82 related articles for article (PubMed ID: 22764537)
1. [Hepatitis B virus core antigen as a carrier for virus-like partical vaccine: a review].
Yang XY; Bo H; Shu YL
Bing Du Xue Bao; 2012 May; 28(3):311-6. PubMed ID: 22764537
[TBL] [Abstract][Full Text] [Related]
2. Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines.
Schödel F; Kelly SM; Peterson D; Milich D; Hughes J; Tinge S; Wirtz R; Curtiss R
Dev Biol Stand; 1994; 82():151-8. PubMed ID: 7958469
[TBL] [Abstract][Full Text] [Related]
3. The hepatitis nucleocapsid as a vaccine carrier moiety.
Milich DR; Peterson DL; Zheng J; Hughes JL; Wirtz R; Schödel F
Ann N Y Acad Sci; 1995 May; 754():187-201. PubMed ID: 7542855
[TBL] [Abstract][Full Text] [Related]
4. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
5. Phage displayed HBV core antigen with immunogenic activity.
Bahadir AO; Balcioglu BK; Uzyol KS; Hatipoglu I; Sogut I; Basalp A; Erdag B
Appl Biochem Biotechnol; 2011 Dec; 165(7-8):1437-47. PubMed ID: 21915589
[TBL] [Abstract][Full Text] [Related]
6. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
7. HBcAg produced in transgenic tobacco triggers Th1 and Th2 response when intramuscularly delivered.
Pyrski M; Rugowska A; Wierzbiński KR; Kasprzyk A; Bogusiewicz M; Bociąg P; Samardakiewicz S; Czyż M; Kurpisz M; Pniewski T
Vaccine; 2017 Oct; 35(42):5714-5721. PubMed ID: 28917537
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco.
Huang Y; Liang W; Wang Y; Zhou Z; Pan A; Yang X; Huang C; Chen J; Zhang D
Viral Immunol; 2005; 18(4):668-77. PubMed ID: 16359233
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
10. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.
Huang Z; Santi L; LePore K; Kilbourne J; Arntzen CJ; Mason HS
Vaccine; 2006 Mar; 24(14):2506-13. PubMed ID: 16417953
[TBL] [Abstract][Full Text] [Related]
11. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
12. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunogenicity of hepatitis B virus core and E antigens.
Milich DR; McLachlan A; Stahl S; Wingfield P; Thornton GB; Hughes JL; Jones JE
J Immunol; 1988 Nov; 141(10):3617-24. PubMed ID: 2460543
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.
Lobaina Y; Palenzuela D; Pichardo D; Muzio V; Guillén G; Aguilar JC
Mol Immunol; 2005 Feb; 42(3):289-94. PubMed ID: 15589316
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus.
Zhang YL; Guo YJ; Wang KY; Lu K; Li K; Zhu Y; Sun SH
Scand J Immunol; 2007 Apr; 65(4):320-8. PubMed ID: 17386022
[TBL] [Abstract][Full Text] [Related]
16. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
17. [Production of hepatitis B virus core particles protein in plants, by using cowpea mosaic virus-based vector].
Meshcheriakova IuA; El'darov MA; Beales L; Skriabin KG; Lomonossoff GP
Vopr Virusol; 2008; 53(3):15-20. PubMed ID: 18590129
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
[TBL] [Abstract][Full Text] [Related]
19. The core antigen of hepatitis B virus as a carrier for immunogenic peptides.
Murray K; Shiau AL
Biol Chem; 1999 Mar; 380(3):277-83. PubMed ID: 10223329
[TBL] [Abstract][Full Text] [Related]
20. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
Yang BF; Zhao HL; Xue C; Xiong XH; Zhang W; Yao XQ; Liu ZM
Vaccine; 2007 May; 25(22):4478-86. PubMed ID: 17467856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
